Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study

Conclusions:
In this pilot study, although both vildagliptin and liraglutide therapies were preferred similarly by the patients and showed effective control of glycemia over 12 weeks, vildagliptin was associated with fewer adverse events and was preferred more by elderly patients.

Source: Therapeutic Advances in Endocrinology and Metabolism - August 4, 2015 Category: Endocrinology Authors: Ludemann, J., Dutting, E. D., Dworak, M. Tags: Original Research Source Type: research